U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H64N14O12S2
Molecular Weight 1069.2209
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESMOPRESSIN

SMILES

c1ccc(cc1)C[C@@]2([H])C(=N[C@@]([H])(CCC(=N)O)C(=N[C@@]([H])(CC(=N)O)C(=N[C@@]([H])(CSSCCC(=N[C@@]([H])(Cc3ccc(cc3)O)C(=N2)O)O)C(=O)N4CCC[C@@]4([H])C(=N[C@]([H])(CCCNC(=N)N)C(=NCC(=N)O)O)O)O)O)O

InChI

InChIKey=NFLWUMRGJYTJIN-PNIOQBSNSA-N
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1

HIDE SMILES / InChI
Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH), which is found naturally in the body and is produced by the hypothalamus and stored, in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the distal convoluted tubule and collecting tubules. Desmopressin also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. It increases urine concentration and decreases urine production. Acetate salt of desmopressin is sold under brand name DDAVP with different formulations: DDAVP Nasal Spray is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. DDAVP Injection is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% and is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. It was suggested that desmopressin-induced relaxation was mediated by a receptor subtype sharing both V1A and V2 pharmacological profiles.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DDAVP (NEEDS NO REFRIGERATION)

Approved Use

Central Diabetes Insipidus: Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate tablets are ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate tablets may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.

Launch Date

2.56867205E11
Primary
DDAVPP

Approved Use

Hemophilia A: DDAVP Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or traumainduced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. 2 DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): DDAVP Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. DDAVP will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved. DDAVP is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen.

Launch Date

4.49452802E11
Primary
DDAVPP

Approved Use

Hemophilia A: DDAVP Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or traumainduced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. 2 DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): DDAVP Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. DDAVP will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved. DDAVP is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen.

Launch Date

4.49452802E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
98 pg/mL
300 μg single, nasal
dose: 300 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DESMOPRESSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
483 pg × h/mL
300 μg single, nasal
dose: 300 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DESMOPRESSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.62 h
300 μg single, nasal
dose: 300 μg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DESMOPRESSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg 1 times / 3 days single, oral
Studied dose
Dose: 6 mg, 1 times / 3 days
Route: oral
Route: single
Dose: 6 mg, 1 times / 3 days
Sources:
unhealthy, 75 years
n = 1
Health Status: unhealthy
Condition: nocturia
Age Group: 75 years
Sex: M
Population Size: 1
Sources:
Other AEs: Agitation, Vomiting...
Other AEs:
Agitation
Vomiting
Sources:
25 ug 1 times / day steady, sublingual
Dose: 25 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 25 ug, 1 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: Nocturia
Age Group: adult
Sex: F
Population Size: 135
Sources:
Other AEs: Headache...
Other AEs:
Headache (below serious, 7 patients)
Sources:
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Other AEs: Tonsillitis, Upper respiratory tract infection...
Other AEs:
Tonsillitis (below serious, 1 patient)
Upper respiratory tract infection (below serious, 1 patient)
Headache (below serious, 1 patient)
Blepharitis (below serious, 1 patient)
Tonsillar hypertrophy (below serious, 1 patient)
Abdominal pain (below serious, 1 patient)
Enterocolitis (below serious, 1 patient)
Stomatitis (below serious, 2 patients)
Dermatitis atopic (below serious, 1 patient)
Skin papilloma (below serious, 1 patient)
Asthenia (below serious, 2 patients)
Malaise (below serious, 1 patient)
Arthropod bite (below serious, 1 patient)
Sources:
0.5 ug/kg 2 times / day multiple, intravenous
MTD
Dose: 0.5 ug/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 0.5 ug/kg, 2 times / day
Sources:
unhealthy, median age 55.5 years
n = 6
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 6
Sources:
DLT: Hyponatremia...
Dose limiting toxicities:
Hyponatremia (16.7%)
Sources:
1 ug/kg 1 times / day multiple, intravenous
Studied dose
Dose: 1 ug/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1 ug/kg, 1 times / day
Sources:
unhealthy, median age 55.5 years
n = 6
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 6
Sources:
DLT: Hyponatremia...
Dose limiting toxicities:
Hyponatremia (grade 3, 33.3%)
Sources:
1 ug/kg 2 times / day multiple, intravenous
Studied dose
Dose: 1 ug/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 ug/kg, 2 times / day
Sources:
unhealthy, median age 55.5 years
n = 2
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 2
Sources:
DLT: Hyponatremia, Hypertonia...
Dose limiting toxicities:
Hyponatremia (grade 3, 100%)
Hypertonia (grade 3, 50%)
Sources:
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Disc. AE: Nasal discomfort, Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Nasal discomfort (0.2%)
Hyponatremia (0.2%)
Dizziness (0.4%)
Blood sodium decreased (0.4%)
Dysuria (0.4%)
Nasal congestion (0.2%)
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Disc. AE: Nasal discomfort, Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Nasal discomfort (0.7%)
Hyponatremia (0.7%)
Dizziness (0.2%)
Blood sodium decreased (0.2%)
Dysuria (0.2%)
Nasal congestion (0.4%)
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Agitation
6 mg 1 times / 3 days single, oral
Studied dose
Dose: 6 mg, 1 times / 3 days
Route: oral
Route: single
Dose: 6 mg, 1 times / 3 days
Sources:
unhealthy, 75 years
n = 1
Health Status: unhealthy
Condition: nocturia
Age Group: 75 years
Sex: M
Population Size: 1
Sources:
Vomiting
6 mg 1 times / 3 days single, oral
Studied dose
Dose: 6 mg, 1 times / 3 days
Route: oral
Route: single
Dose: 6 mg, 1 times / 3 days
Sources:
unhealthy, 75 years
n = 1
Health Status: unhealthy
Condition: nocturia
Age Group: 75 years
Sex: M
Population Size: 1
Sources:
Headache below serious, 7 patients
25 ug 1 times / day steady, sublingual
Dose: 25 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 25 ug, 1 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: Nocturia
Age Group: adult
Sex: F
Population Size: 135
Sources:
Abdominal pain below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Arthropod bite below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Blepharitis below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Dermatitis atopic below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Enterocolitis below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Headache below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Malaise below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Skin papilloma below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Tonsillar hypertrophy below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Tonsillitis below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Upper respiratory tract infection below serious, 1 patient
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Asthenia below serious, 2 patients
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Stomatitis below serious, 2 patients
240 ug 1 times / day steady, sublingual (max)
Dose: 240 ug, 1 times / day
Route: sublingual
Route: steady
Dose: 240 ug, 1 times / day
Sources:
unhealthy, children|adolescents
n = 45
Health Status: unhealthy
Condition: Nocturnal enuresis
Age Group: children|adolescents
Population Size: 45
Sources:
Hyponatremia 16.7%
DLT
0.5 ug/kg 2 times / day multiple, intravenous
MTD
Dose: 0.5 ug/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 0.5 ug/kg, 2 times / day
Sources:
unhealthy, median age 55.5 years
n = 6
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 6
Sources:
Hyponatremia grade 3, 33.3%
DLT
1 ug/kg 1 times / day multiple, intravenous
Studied dose
Dose: 1 ug/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1 ug/kg, 1 times / day
Sources:
unhealthy, median age 55.5 years
n = 6
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 6
Sources:
Hyponatremia grade 3, 100%
DLT
1 ug/kg 2 times / day multiple, intravenous
Studied dose
Dose: 1 ug/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 ug/kg, 2 times / day
Sources:
unhealthy, median age 55.5 years
n = 2
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 2
Sources:
Hypertonia grade 3, 50%
DLT
1 ug/kg 2 times / day multiple, intravenous
Studied dose
Dose: 1 ug/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 1 ug/kg, 2 times / day
Sources:
unhealthy, median age 55.5 years
n = 2
Health Status: unhealthy
Condition: bleeding
Age Group: median age 55.5 years
Sex: M+F
Population Size: 2
Sources:
Hyponatremia 0.2%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Nasal congestion 0.2%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Nasal discomfort 0.2%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Blood sodium decreased 0.4%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Dizziness 0.4%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Dysuria 0.4%
Disc. AE
0.75 ug 1 times / day multiple, intranasal
Recommended
Dose: 0.75 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 0.75 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 454
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 454
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Blood sodium decreased 0.2%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Dizziness 0.2%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Dysuria 0.2%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Nasal congestion 0.4%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Hyponatremia 0.7%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Nasal discomfort 0.7%
Disc. AE
1.5 ug 1 times / day multiple, intranasal
Recommended
Dose: 1.5 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 1.5 ug, 1 times / day
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
unhealthy, median age 65.5 years
n = 448
Health Status: unhealthy
Condition: nocturia
Age Group: median age 65.5 years
Sex: M+F
Population Size: 448
Sources: Page: nda/2017/201656Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
PubMed

PubMed

TitleDatePubMed
Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression.
2004 Jan
Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
2006 Apr 5
Characterization of a novel and selective V1B receptor antagonist.
2008
Patents

Patents

Sample Use Guides

Hemophilia A and von Willebrand’s Disease (Type I): DDAVP Injection 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg DDAVP/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Blood pressure and pulse should be monitored during infusion. If DDAVP Injection 4 mcg/mL is used preoperatively, it should be administered 30 minutes prior to the scheduled procedure. Diabetes Insipidus: This formulation is administered subcutaneously or by direct intravenous injection. DDAVP Injection 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1 mL (4.0 mcg) daily, administered intravenously or subcutaneously, usually in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For patients who have been controlled on intranasal DDAVP and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose. Central Diabetes Insipidus: The dosage of DDAVP Tablets must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients previously on intranasal DDAVP therapy should begin tablet therapy twelve hours after the last intranasal dose. During the initial dose titration period, patients should be 6 observed closely and appropriate safety parameters measured to assure adequate response. Central Cranial Diabetes Insipidus: DDAVP Nasal Spray dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients with nasal congestion and blockage have often responded well to intranasal DDAVP. The usual dosage range in adults is 0.1 to 0.4 mL daily, either as a single dose or divided into two or three doses. Most adults require 0.2 mL daily in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For children aged 3 months to 12 years, the usual dosage range is 0.05 to 0.3 mL daily, either as a single dose or divided into two doses. About 1/4 to 1/3 of patients can be controlled by a single daily dose of DDAVP administered intranasally.
Route of Administration: Other
It was investigated the influence of desmopressin on platelet endothelial interactions in vitro. (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. DDAVP increases von Willebrand factor (VWF) on endothelial cells (ECs) and in plasma. VWF could facilitate platelet deposition on subendothelial collagen. VWF also facilitates platelet/EC interactions. Therefore DDAVP could precipitate thromboembolic events. Resting or TRAP-activated platelets and EC were treated individually or simultaneously with 0.4 ng/ml DDAVP. Fluorophor-labeled platelets (10(6)/ml) were resuspended in reconstituted blood and superfused across EC and collagen in an in vitro flow chamber model at arterial shear (320 s(-1)). Adhesion of platelets to the respective surface was recorded fluorescence microscopically and platelet covered area was assessed. DDAVP pretreatment of platelets did not affect adhesiveness of resting or TRAP-activated platelets for collagen or EC. DDAVP has no direct effect on platelets. Blood samples from DDAVP-treated patients do not exhibit significantly augmented platelet deposition on collagen ex vivo.
Name Type Language
DESMOPRESSIN
EP   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
DESMOPRESSIN [WHO-DD]
Common Name English
DESMOPRESSIN [MART.]
Common Name English
DESMOPRESSIN [INN]
Common Name English
VASOPRESSIN, 1-(3-MERCAPTOPROPANOIC ACID)-8-D-ARGININE-
Common Name English
DESMOPRESSIN [VANDF]
Common Name English
H01BA02
Code English
DESMOPRESSIN [EP MONOGRAPH]
Common Name English
1-(3-MERCAPTOPROPIONIC ACID)-8-D-ARGININE-VASOPRESSIN
Common Name English
DESMOPRESSIN [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000006320
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NCI_THESAURUS C80212
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000006320
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000006320
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000006320
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175905
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175914
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175915
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175915
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000006320
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
WHO-VATC QH01BA02
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175916
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
WHO-ATC H01BA02
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
NDF-RT N0000175914
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
Code System Code Type Description
INN
3799
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
DRUG BANK
DB00035
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
MERCK INDEX
M4196
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1429
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
PUBCHEM
5311065
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
WIKIPEDIA
DESMOPRESSIN
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
NCI_THESAURUS
C61701
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
CAS
16679-58-6
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
DRUG CENTRAL
817
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
RXCUI
3251
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000175914
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY Increased Coagulation Factor VIII Activity [PE]
LACTMED
Desmopressin
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
EPA CompTox
16679-58-6
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
ECHA (EC/EINECS)
240-726-7
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
EVMPD
SUB07001MIG
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY
FDA UNII
ENR1LLB0FP
Created by admin on Fri Jun 25 21:11:19 UTC 2021 , Edited by admin on Fri Jun 25 21:11:19 UTC 2021
PRIMARY